Radio Frequency Identification (RFID) in Pharmaceuticals Market Report 2026

The radio frequency identification (rfid) in pharmaceuticals market size has grown rapidly in recent years. It will grow from $6.08 billion in 2025 to $6.74 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing regulatory focus on drug traceability, rising incidents of counterfeit medicines, expansion of global pharmaceutical supply chains, adoption of serialization mandates, growing hospital inventory complexity.

The radio frequency identification (rfid) in pharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.07 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing investments in digital pharmaceutical logistics, rising demand for real-time supply chain visibility, expansion of rfid-enabled smart hospitals, growing adoption of blockchain-linked traceability systems, increasing regulatory harmonization across regions. Major trends in the forecast period include increasing adoption of end-to-end drug track and trace systems, rising use of rfid for anti-counterfeiting measures, growing integration of rfid with serialization platforms, expansion of real-time pharmaceutical inventory visibility, enhanced focus on cold chain monitoring accuracy.

The rising incidences of counterfeit drugs are expected to drive the growth of the radio frequency identification (RFID) in pharmaceuticals market going forward. Counterfeit drugs, also referred to as counterfeit medicines, are pharmaceutical products that are intentionally and fraudulently mislabeled regarding their identity or source. The increase in counterfeit drugs is largely attributed to the rapid expansion of online pharmacies, which has made it easier for counterfeiters to distribute fake medicines directly to consumers, bypassing traditional regulatory controls and complicating detection. Radio frequency identification (RFID) in pharmaceuticals helps combat counterfeit drugs by providing secure, traceable data that verifies product authenticity throughout the supply chain. For example, in December 2024, according to the American Chemical Society, a US-based nonprofit scientific society, 6,987 counterfeit drug incidents were reported across 142 countries in 2023, marking a 4% increase from 2022. Therefore, the rising incidences of counterfeit drugs are propelling the growth of the radio frequency identification (RFID) in pharmaceuticals market.

Key companies operating in the radio frequency identification (RFID) in pharmaceuticals market are focusing on developing advanced RFID-enabled labels to improve product traceability, enhance inventory management, and address the growing threat of counterfeit drugs. RFID-enabled labels are smart tags that use radio frequency technology to wirelessly identify, track, and verify pharmaceutical products across the supply chain. For instance, in May 2023, Fresenius Kabi AG, a Germany-based pharmaceutical company, introduced Rocuronium Bromide Injection with advanced RFID-enabled labeling to improve medication tracking, inventory management, and patient safety in healthcare settings. Supplied as a 50 mg per 5 mL multiple-dose vial for intravenous administration by trained medical professionals, the injection’s RFID-enabled smart labeling allows real-time tracking, streamlines inventory processes, and helps reduce medication errors.

In April 2023, Impinj Inc., a US-based technology company, acquired Voyantic Ltd. for an undisclosed amount. Through this acquisition, Impinj Inc. aims to strengthen its position in the RFID industry and expand its portfolio with advanced RFID testing and measurement solutions to enhance performance and innovation. Voyantic Ltd. is a Finland-based company providing RFID testing, measurement, and quality assurance solutions for RFID tags and systems in pharmaceuticals.

Major companies operating in the radio frequency identification (rfid) in pharmaceuticals market are Fujitsu Limited, NXP Semiconductors NV, Avery Dennison Corporation, Zebra Technologies Corporation, CCL Industries Inc., HID Global Corporation, Checkpoint Systems Inc, Datalogic SpA, Impinj Inc, Schreiner Group GmbH & Co KG, Invengo Information Technology Co Ltd, GAO RFID Inc., Lowry Solutions Inc., Terso Solutions Inc., Xerafy Singapore Pte Ltd., Tageos SAS, SML Group Limited, Syrma SGS Technology Limited, Omnia Technologies Private Limited, identytag GmbH & Co KG.

North America was the largest region in the radio frequency identification (RFID) in pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radio frequency identification (rfid) in pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radio frequency identification (rfid) in pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the RFID in pharmaceuticals market by increasing the cost of imported semiconductor chips, RFID tags, readers, antennas, and data management hardware used across pharmaceutical manufacturing and distribution systems. Pharmaceutical producers and logistics operators in North America and Europe are most affected due to dependence on imported electronic components, while Asia-Pacific faces pricing pressure on tag and reader exports. These tariffs are raising implementation costs and slowing large-scale rollout initiatives. However, they are also encouraging domestic electronics manufacturing, regional sourcing of RFID components, and increased investment in locally developed compliance-focused tracking solutions.

The radio frequency identification (rfid) in pharmaceuticals market research report is one of a series of new reports that provides radio frequency identification (rfid) in pharmaceuticals market statistics, including radio frequency identification (rfid) in pharmaceuticals industry global market size, regional shares, competitors with a radio frequency identification (rfid) in pharmaceuticals market share, detailed radio frequency identification (rfid) in pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radio frequency identification (rfid) in pharmaceuticals industry. This radio frequency identification (rfid) in pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radio frequency identification (RFID) in pharmaceuticals is a wireless technology that uses electronic tags with chips and antennas to automatically identify, track, and manage medicines throughout the supply chain, from manufacturing to end use. This technology enhances patient safety, ensures regulatory compliance, and streamlines operations by enabling rapid, contactless, and accurate verification of drug authenticity and movement at every stage.

The primary types of radio frequency identification (RFID) in pharmaceuticals include chipped RFID and chipless RFID. Chipped RFID uses tags embedded with microchips and antennas to store and wirelessly transmit unique identification data, tracking information, and product history, which can be read by compatible RFID readers for real-time authentication, monitoring, and management of pharmaceutical products. These solutions are supported by components such as RFID tags, RFID readers, middleware software, integration services, and data management software, and are deployed in compliance with regulations including FDA standards, the European Union Falsified Medicines Directive, good distribution practices, serialization requirements, and tracking and tracing regulations. Applications include drug track-and-trace systems, asset tracking, patient safety, and other uses, serving end users such as pharmaceutical manufacturers, hospitals and healthcare providers, pharmacies and drug wholesalers, research and development laboratories, and logistics and supply chain companies.

The radio frequency identification (RFID) in pharmaceuticals market consists of revenues earned by entities providing services such as drug authentication, real-time tracking and tracing of medications, inventory management, anti-counterfeiting solutions, and regulatory compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. The radio frequency identification (RFID) in pharmaceuticals market also includes sales of fixed readers, tracing systems, and verification systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.